These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33705901)

  • 1. The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition.
    Chen H; Wang B; Li P; Yan H; Li G; Huang H; Lu Y
    Bioorg Med Chem Lett; 2021 May; 40():127924. PubMed ID: 33705901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.
    Ha-Duong NT; Dijols S; Marques-Soares C; Minoletti C; Dansette PM; Mansuy D
    J Med Chem; 2001 Oct; 44(22):3622-31. PubMed ID: 11606127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of novel tetrahydrothieno[2,3-c]pyridine-3-carboxamide based Mycobacterium tuberculosis pantothenate synthetase inhibitors: molecular hybridization from known antimycobacterial leads.
    Samala G; Devi PB; Nallangi R; Sridevi JP; Saxena S; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2014 Mar; 22(6):1938-47. PubMed ID: 24565972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9.
    Mancy A; Dijols S; Poli S; Guengerich P; Mansuy D
    Biochemistry; 1996 Dec; 35(50):16205-12. PubMed ID: 8973193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of new sulfaphenazole derivatives with human liver cytochrome p450 2Cs: structural determinants required for selective recognition by CYP 2C9 and for inhibition of human CYP 2Cs.
    Ha-Duong NT; Marques-Soares C; Dijols S; Sari MA; Dansette PM; Mansuy D
    Arch Biochem Biophys; 2001 Oct; 394(2):189-200. PubMed ID: 11594733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substituted
    Bouz G; Juhás M; Pausas Otero L; Paredes de la Red C; Janďourek O; Konečná K; Paterová P; Kubíček V; Janoušek J; Doležal M; Zitko J
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31905775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enantiopure antituberculosis candidates synthesized from (-)-fenchone.
    Dobrikov GM; Valcheva V; Nikolova Y; Ugrinova I; Pasheva E; Dimitrov V
    Eur J Med Chem; 2014 Apr; 77():243-7. PubMed ID: 24642567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and evaluation of substituted nicotinamide adenine dinucleotide (NAD
    Wang X; Ahn YM; Lentscher AG; Lister JS; Brothers RC; Kneen MM; Gerratana B; Boshoff HI; Dowd CS
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4426-4430. PubMed ID: 28827112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New INH-pyrazole analogs: Design, synthesis and evaluation of antitubercular and antibacterial activity.
    Nayak N; Ramprasad J; Dalimba U
    Bioorg Med Chem Lett; 2015 Dec; 25(23):5540-5. PubMed ID: 26520663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thienopyrimidines as novel inhibitors of Mycobacterium tuberculosis: synthesis and in-vitro studies.
    Rashmi P; Nargund LV; Hazra K; Chandra JN
    Arch Pharm (Weinheim); 2011 Jul; 344(7):459-65. PubMed ID: 21598298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
    Lokesh BVS; Prasad YR; Shaik AB
    Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of antimycobacterial activity of riboflavin derivatives.
    Harale B; Kidwai S; Ojha D; Singh M; Chouhan DK; Singh R; Khedkar V; Rode AB
    Bioorg Med Chem Lett; 2021 Sep; 48():128236. PubMed ID: 34242760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New chalcone-sulfonamide hybrids exhibiting anticancer and antituberculosis activity.
    Castaño LF; Cuartas V; Bernal A; Insuasty A; Guzman J; Vidal O; Rubio V; Puerto G; Lukáč P; Vimberg V; Balíková-Novtoná G; Vannucci L; Janata J; Quiroga J; Abonia R; Nogueras M; Cobo J; Insuasty B
    Eur J Med Chem; 2019 Aug; 176():50-60. PubMed ID: 31096118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A note on the antitubercular activities of 1-aryl-5-benzylsulfanyltetrazoles.
    Adamec J; Waisser K; Kunes J; Kaustová J
    Arch Pharm (Weinheim); 2005 Aug; 338(8):385-9. PubMed ID: 16041837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship studies on 3,5-dinitrophenyl tetrazoles as antitubercular agents.
    Němeček J; Sychra P; Macháček M; Benková M; Karabanovich G; Konečná K; Kavková V; Stolaříková J; Hrabálek A; Vávrová K; Soukup O; Roh J; Klimešová V
    Eur J Med Chem; 2017 Apr; 130():419-432. PubMed ID: 28279848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, biological evaluation and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis.
    Castagnolo D; De Logu A; Radi M; Bechi B; Manetti F; Magnani M; Supino S; Meleddu R; Chisu L; Botta M
    Bioorg Med Chem; 2008 Sep; 16(18):8587-91. PubMed ID: 18752962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, biological evaluation, and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis: part 2. Synthesis of rigid pyrazolones.
    Castagnolo D; Manetti F; Radi M; Bechi B; Pagano M; De Logu A; Meleddu R; Saddi M; Botta M
    Bioorg Med Chem; 2009 Aug; 17(15):5716-21. PubMed ID: 19581099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and antitubercular activity of 6-chloro (unsubstituted)- 2-methoxy-9-substituted acridine derivatives.
    Aly EI; Abadi AH
    Arch Pharm Res; 2004 Jul; 27(7):713-9. PubMed ID: 15356996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
    Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis.
    Park Y; Pacitto A; Bayliss T; Cleghorn LA; Wang Z; Hartman T; Arora K; Ioerger TR; Sacchettini J; Rizzi M; Donini S; Blundell TL; Ascher DB; Rhee K; Breda A; Zhou N; Dartois V; Jonnala SR; Via LE; Mizrahi V; Epemolu O; Stojanovski L; Simeons F; Osuna-Cabello M; Ellis L; MacKenzie CJ; Smith AR; Davis SH; Murugesan D; Buchanan KI; Turner PA; Huggett M; Zuccotto F; Rebollo-Lopez MJ; Lafuente-Monasterio MJ; Sanz O; Diaz GS; Lelièvre J; Ballell L; Selenski C; Axtman M; Ghidelli-Disse S; Pflaumer H; Bösche M; Drewes G; Freiberg GM; Kurnick MD; Srikumaran M; Kempf DJ; Green SR; Ray PC; Read K; Wyatt P; Barry CE; Boshoff HI
    ACS Infect Dis; 2017 Jan; 3(1):18-33. PubMed ID: 27704782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.